Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 2/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.33 |
| ▸ | WDR5 | P61964 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | CCR6 | P51684 | 1/20 | 0.32 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL345772 | 1.00 | MAPT (0.35) | MAPTHTR7SLC6A9WDR5POLB | |
| SCHEMBL345426 | 0.79 | HTR7 (0.43) | MAPTHTR7SLC6A9WDR5SLC6A5 | |
| SCHEMBL345427 | 0.79 | HTR7 (0.43) | MAPTHTR7SLC6A9WDR5SLC6A5 | |
| SCHEMBL2331165 | 0.76 | MAPT (0.42) | MAPTHTR7SLC6A9WDR5ALDH1A1 | |
| SCHEMBL15662852 | 0.76 | MAPT (0.42) | MAPTHTR7SLC6A9WDR5ALDH1A1 | |
| SCHEMBL345257 | 0.71 | PKM (0.35) | ALDH1A1KMT2A | |
| SCHEMBL345630 | 0.69 | PKM (0.36) | ALDH1A1 | |
| SCHEMBL345792 | 0.68 | PKM (0.36) | ALDH1A1 | |
| SCHEMBL345635 | 0.67 | HTR7 (0.40) | MAPTHTR7SLC6A9POLBSLC6A5 | |
| SCHEMBL16305327 | 0.65 | PDE3B (0.47) | HTR7SLC6A9WDR5SLC6A5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | INTS9, CDK8, SCN8A | MAPT 4026/4885HTR7 458/4885SLC6A9 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.